Related Experiment Videos
[Metoprolol, a new effective antimigraine agent]
1Laboratoires Astra France, Tour Avenir Quest, Nanterre.
Presse Medicale (Paris, France : 1983)
|October 15, 1988
Summary
Metoprolol effectively prevents migraines. In trials, 200 mg daily proved superior to placebo and comparable to other migraine preventatives, establishing its role in prophylaxis.
Area of Science:
- Neurology
- Pharmacology
Background:
- Migraine is a common neurological disorder.
- Prophylactic treatment is crucial for managing frequent migraine attacks.
Purpose of the Study:
- To evaluate the efficacy of metoprolol as a prophylactic treatment for migraine.
- To compare metoprolol with placebo and other established migraine prophylactic medications.
Main Methods:
- Double-blind comparative trials involving over 500 patients.
- Investigated slow-release metoprolol at doses of 100 mg/day and 200 mg/day.
- Compared metoprolol against placebo, propranolol, flunarizine, clonidine, clomipramine, and pizotifen.
Main Results:
- Metoprolol 200 mg/day was significantly more effective than placebo and comparable to propranolol 160 mg/day and flunarizine 10 mg/day.
- Metoprolol 100 mg/day showed significant efficacy over clonidine and clomipramine but was similar to placebo, propranolol 80 mg/day, and pizotifen 1.5 mg/day.
Conclusions:
- Metoprolol is a useful prophylactic treatment for migraine.
- Metoprolol is comparable to established migraine prophylactic agents like propranolol and pizotifen.